Doctor of Osteopathy Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Louise Doyle

Ophthalmology Columbus, OH Doctor of Osteopathy

NPI 1265503254 CMS profile 57828

4830 Knightsbridge Blvd Ste G, Columbus, OH 43214

Open in the dashboard

General payments

$1,534

83 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Louise Doyle of Columbus, OH is reported in the CMS Open Payments database as having received $1,534 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 53rd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $29 2
2023 General $157 8
2022 General $260 13
2021 General $171 9
2020 General $387 22
2019 General $529 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louise Doyle
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Louise Doyle were reported at $0. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Louise Doyle Ophthalmology median Middle half National median
2019 $529 $258 $104–$655 $163
2020 $387 $126 $45–$321 $114
2021 $171 $205 $76–$534 $132
2022 $260 $266 $100–$678 $149
2023 $157 $308 $117–$745 $160
2024 $29 $340 $127–$846 $164
2025 $0 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Kala Pharmaceuticals, Inc. $317 18 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $289 17 payments
  3. Novartis Pharmaceuticals Corporation $188 10 payments
  4. Eyevance Pharmaceuticals LLC $137 9 payments
  5. Alcon Vision LLC $107 5 payments
  6. TissueTech, Inc. $98 5 payments
  7. Sun Pharmaceutical Industries Inc. $93 6 payments
  8. Regeneron Healthcare Solutions, Inc. $88 1 payment
  9. Oyster Point Pharma, Inc. $72 4 payments
  10. Johnson & Johnson Surgical Vision, Inc. $51 3 payments
  11. Other $92 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,534 83 payments
Products named General payments · program years 2019–2024
  1. INVELTYS $317 18 payments
  2. LOTEMAX SM $180 11 payments
  3. XIIDRA $122 6 payments
  4. PROLENSA $113 6 payments
  5. EYLEA $88 1 payment
  6. Cequa $80 5 payments
  7. TYRVAYA $72 4 payments
  8. PROKERA $69 3 payments
  9. AMNIOGRAFT $69 3 payments
  10. Flarex $68 4 payments
  11. Other $608 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record